Processa Pharmaceuticals, Inc. (PCSA)
2025-06-30 | ||||
|---|---|---|---|---|
| Other income (expense), net | 16,865 | |||
| Research and development expenses | 2,447,286 | |||
| General and administrative expenses | 1,503,497 | |||
| Operating loss | -3,950,783 | |||
| Net loss | -3,933,918 | |||
| Net loss per common share - basic | -0.25 | |||
| Net loss per common share - diluted | -0.25 | |||
| Weighted average common shares used to compute net loss applicable to common shares - basic | 15,569,312 | |||
| Weighted average common shares used to compute net loss applicable to common shares - diluted | 15,569,312 | |||